Vimarsana
Biggest News Aggregation in the World

Page 4 - Oaktree Acquisition News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oaktree Acquisition. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oaktree Acquisition Today - Breaking & Trending Today

STADA and Alvotech Secure Approval for Uzpruvo, Europe's - Vimarsana News

STADA and Alvotech Secure Approval for Uzpruvo, Europe's

Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology,...

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® - Vimarsana News

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® in healthy adult subjects, met its primary endpoint Alvotech , a global biotech company specializing in...

Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update - Vimarsana News

Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update

Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the...

Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update - Vimarsana News

Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update

Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the first for a biosimilar to Stelara® (ustekinumab)The European Medicines Agency proposed market authorization for AVT04 in the 30 member states of the European Economic Area, pending a final decision by the European Commission Approvability of AVT02 and AVT04 in the U.S. now pending satisfactory US Food

Source: yahoo.com
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the ... - Vimarsana News

Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the ...

PrJamteki TM is thesecond biosimilar developedunderthispartnershipthatreceivesmarketingauthorization inCanada.